Novo Nordisk sells two weight loss drugs that are of the same class in two doses - liraglutide as Saxenda, and semaglutide at a higher and more effective dose as Wegovy. It is easily available at pharmacies, and insurance companies cover it for people with diabetes.

As a diabetes drug, it is called Ozempic and has a list price of $892 for four weeks. The company sells a drug, semaglutide, for both diabetes and for obesity. The workaround exploits quirks in the way Novo Nordisk markets its drugs. Kahan said.Īnd that, he adds, is a perception many patients, as well as doctors, share, making them reluctant to seek medical help or prescription medications. “The perception is, ‘If you are heavy, pull yourself up from your bootstraps and try harder,’” Dr. That is about the same percentage as those who get bariatric surgery, which most insurers, including Medicare, pay for. Still, obesity medicine doctors say, they doubt that the number has changed much from the earlier studies that found that less than 1 percent who are eligible obtained one of these drugs. “It’s the biggest chronic disease of our time, and no one is learning anything about it,” she said.ĭata on medication use by patients predate the newer, more effective and safe drugs made by Novo Nordisk and Eli Lilly. Just 1 percent of doctors in the United States are trained in obesity medicine. The medical system bears much of the blame, Dr.

approved drugs, many think they are “unsafe or not well studied and that everyone regains their weight.” And, he added, even if doctors and patients know there are F.D.A. Scott Kahan, an obesity medicine specialist in Washington, D.C. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital and Harvard Medical School.īut even if a patient’s insurer will cover weight loss drugs, most doctors do not suggest the drugs and most patients do not ask for them, as they fail to realize there are good treatment options, said Dr. “Access to medicines for the treatment of obesity is dismal in this country,” said Dr. Something physical is holding them back.” “It’s not that they don’t have willpower. Louis Aronne, an obesity medicine specialist who directs the comprehensive weight control center at Weill Cornell Medicine. “The evidence is now overwhelming that there are physical changes in weight regulating pathways that make it difficult for people to lose weight and maintain their weight loss,” said Dr. Many suffer from medical conditions that are linked to obesity, including diabetes, joint and back pain and heart disease, and those conditions often improve with weight loss. No one disputes the problem - more than 40 percent of Americans have obesity, and most have tried repeatedly to lose weight and keep it off, only to fail.

They also have been lobbying Congress to pass a bill that has languished through three administrations that would require Medicare to pay for the drugs.īut for now, the status quo has not budged. Apovian prescribed, and patient advocacy groups have been aggressively lobbying insurers to pay for weight-loss drugs. Novo-Nordisk, the maker of the medicine Dr.

Weight loss medication